Listing Category
Description
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension(PAH) standard of care or PAH-specific background oral therapy in subjects with World Health Organization(WHO) Group 1 pulmonary hypertension(ADVANCE Outcomes)